Press release from Companies

Publicerat: 2025-04-01 13:18:19

Eevia Health Plc: Good Start to Q2-25 for Eevia with New Sales Orders Totaling MSEK 1.4 (KEUR 130)

Eevia Health Plc ("Eevia" or "the Company") has received multiple new sales orders totalling KEUR 130 (c. KSEK 1.4) from various European and U.S. customers. This follows strong order growth in Q1-25, marking a positive start to the second quarter.

The largest order was placed by a Swedish brand owner with a presence in over 50,000 retail outlets across 38 countries. The order is for Feno-Myrtillus® 1, a bilberry extract standardized for anthocyanins, with deliveries scheduled for April and May. Additional orders came from customers in Finland, the U.S., and a new client in France. These include orders for:

 

  • Feno-Cerasus™ 5 Organic – a Tart cherry extract (5% polyphenols)
  • Fenoprolic™ 70 Organic – a Pine bark extract (standardized for OPCs)
  • Feno-Vitis™ 5 Organic – a Lingonberry extract (standardized for PACs)

 

The new sales order if for a total of KEUR 130. With almost all product volumes in stock, Eevia ensures immediate shipments, avoiding raw material procurement delays. Inventory sales also support cash flow improvements and help reduce stock levels, aligning with the Company’s turnaround strategy. Eevia remains focused on expanding its European and global footprint, leveraging a growing customer base to drive sustained growth.

 

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com                      

Telephone: +358 400 22 5967                         

 

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.

Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

 

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.

Läs mer hos Cision
Läs mer om Eevia Health Plc